Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Original Investigation entitled “Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss: The Idiopathic Intracranial Hypertension Treatment Trial” published in the April 23/30, 2014, issue of JAMA (2014;311:1641-1651. doi:10.1001/jama.2014.3312), data entry errors on cerebrospinal fluid (CSF) occurred. In Table 1, CSF pressure for the acetazolamide group should be 348.9 (94.1) mm H2O. In the Results section, the paragraph on CSF pressure should read as follows: “Only 85 participants (47 [55%] in the acetazolamide group and 38 [48%] in the placebo group) agreed to a lumbar puncture at month 6. The adjusted mean change in CSF pressure was −112.3 mm H2O (from 357.2 mm H2O at baseline to 244.9 mm H2O at month 6) in the acetazolamide group and −52.4 mm H2O (from 357.2 mm H2O at baseline to 304.8 mm H2O at month 6) in the placebo group (treatment effect, −59.9 mm H2O; 95% CI, −96.4 to −23.4 mm H2O; P = .002).” This article was corrected online.
CSF Data Errors in Text and Table. JAMA. 2014;312(10):1061. doi:10.1001/jama.2014.10255